Therapeutic Classification: antiparkinson agents, antidepressants
Pharmacologic Classification: monoamine oxidase type b inhibitors
REMS
Absorption: Well absorbed following oral administration. 2530% of patch content is absorbed; levels are higher than those following oral administration because there is less first-pass hepatic metabolism.
Distribution: Widely distributed to tissues; crosses the blood-brain barrier.
Half-Life: Oral: 10 hr; Transdermal: 20 hr.
(beneficial effects in Parkinsons disease)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 23 days‡ | 4090 min‡ | unknown |
Orally disintegrating | 5 min‡ | 1015 min‡ | unknown |
Transdermal | unknown | ≥2 wk‡ | unknown |
‡Beneficial effects in Parkinsons disease; ‡ Antidepressant effects
Contraindicated in:
Use Cautiously in:
CV: orthostatic hypotension
Derm:
Transdermal
application site reactions, acne, ecchymoses, pruritus, sweatingGI: nausea, abdominal pain, diarrhea, dry mouth
Neuro: aggression, agitation, confusion, delirium, delusions, disorientation, dizziness, fainting, hallucinations, headache, insomnia, paranoia, psychosis, sedation, SEROTONIN SYNDROME, urges (gambling, sexual), vivid dreams
Drug-drug:
Drug-Natural Products:
Depression
Toxicity and Overdose: